

Thomas R O'brien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7182857/publications.pdf>

Version: 2024-02-01

45
papers

2,497
citations

471509

17
h-index

243625

44
g-index

46
all docs

46
docs citations

46
times ranked

3963
citing authors

#	ARTICLE	IF	CITATIONS
1	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. <i>Nature Genetics</i> , 2013, 45, 164-171.	21.4	843
2	Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. <i>Nature Medicine</i> , 1996, 2, 412-417.	30.7	676
3	COVID-19 and emerging viral infections: The case for interferon lambda. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	177
4	IFNL4: The Paradoxical New Member of the Interferon Lambda Family. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 829-838.	1.2	130
5	Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, 71, 1410-1412.	5.8	88
6	Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. <i>Journal of Hepatology</i> , 2015, 63, 1103-1110.	3.7	61
7	Genetic effects on HIV disease progression. <i>Nature Medicine</i> , 1998, 4, 536-536.	30.7	49
8	Recent Decline in Hepatocellular Carcinoma Rates in the United States. <i>Gastroenterology</i> , 2020, 158, 1503-1505.e2.	1.3	36
9	Shortening the duration of therapy for chronic hepatitis C infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 832-836.	8.1	35
10	Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. <i>Gastroenterology</i> , 2019, 156, 400-417.	1.3	35
11	No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA $\leq 6,000,000$ IU/mL. <i>Hepatology</i> , 2016, 63, 28-30.	7.3	32
12	Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Gastroenterology</i> , 2019, 156, 1496-1507.e7.	1.3	32
13	An IL28B Genotype-Based Clinical Prediction Model for Treatment of Chronic Hepatitis C. <i>PLoS ONE</i> , 2011, 6, e20904.	2.5	25
14	Hepatitis D Viremia Among Injection Drug Users in San Francisco. <i>Journal of Infectious Diseases</i> , 2018, 217, 1902-1906.	4.0	24
15	Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. <i>Cancer</i> , 2019, 125, 2621-2630.	4.1	24
16	Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. <i>Journal of Viral Hepatitis</i> , 2019, 26, 738-749.	2.0	20
17	IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir. <i>Gastroenterology</i> , 2017, 153, 1694-1695.	1.3	19
18	Race or genetic makeup for hepatitis C virus treatment decisions?. <i>Hepatology</i> , 2017, 65, 2124-2125.	7.3	18

#	ARTICLE	IF	CITATIONS
19	Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression. <i>Immunogenetics</i> , 2003, 55, 157-164.	2.4	15
20	Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. <i>International Journal of Cancer</i> , 2019, 145, 2360-2371.	5.1	14
21	IFNL4: Notable variants and associated phenotypes,. <i>Gene</i> , 2020, 730, 144289.	2.2	14
22	Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus and hepatitis C virus-infected individuals. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 833-842.	3.7	14
23	Hepatocellular Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 67-73.	2.0	12
24	Prediagnostic serum polychlorinated biphenyl concentrations and primary liver cancer: A case-control study nested within two prospective cohorts. <i>Environmental Research</i> , 2020, 187, 109690.	7.5	10
25	Declining US Hepatocellular Carcinoma Rates, 2014-2017. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e330-e334.	4.4	9
26	Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. <i>PLoS ONE</i> , 2016, 11, e0166036.	2.5	9
27	Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?. <i>Hepatology</i> , 2020, 72, 794-796.	7.3	7
28	Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. <i>American Journal of Hematology</i> , 1995, 49, 201-206.	4.1	6
29	Interferon Lambda 4 Genotype Is Not Associated with Recurrence of Oral or Genital Herpes. <i>PLoS ONE</i> , 2015, 10, e0138827.	2.5	6
30	Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-Î”G and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 102-109.	4.0	6
31	Intracellular Accumulation of IFN-Î”4 Induces ER Stress and Results in Anti-Cirrhotic but Pro-HCV Effects. <i>Frontiers in Immunology</i> , 2021, 12, 692263.	4.8	6
32	Beasley's 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention. <i>Cancer Epidemiology</i> , 2018, 53, 195-199.	1.9	5
33	Meeting Overview: Interferon Lambda Disease Impact and Therapeutic Potential. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 586-591.	1.2	5
34	A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2021, 223, 2090-2098.	4.0	5
35	Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection. <i>Genes and Immunity</i> , 2020, 21, 348-359.	4.1	5
36	Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. <i>Scientific Reports</i> , 2021, 11, 21194.	3.3	5

#	ARTICLE	IF	CITATIONS
37	Impact of IFNL4 -â†G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 34-36.	1.8	4
38	Relationship of Genotype for HLA B*57 and IFNL4 With Disease Progression in Female HIV Controllers. <i>Clinical Infectious Diseases</i> , 2017, 65, 1243-1244.	5.8	3
39	What Have We Learned from Studies of IFN-Î» Variants and Hepatitis C Virus Infection?. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 618-626.	1.2	3
40	Death certificates compared to SEERâ€Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 934-941.	2.0	3
41	The Impact of IFN-Î»4 on the Adaptive Immune Response to SARS-CoV-2 Infection. <i>Journal of Interferon and Cytokine Research</i> , 2021, 41, 407-414.	1.2	3
42	The role of IFNL4 in liver inflammation and progression of fibrosis. <i>Genes and Immunity</i> , 2022, 23, 111-117.	4.1	2
43	Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1583-1584.	3.7	1
44	What makes the hepatitis C virus evolve?. <i>ELife</i> , 2019, 8, .	6.0	1
45	CCR5-Î»32 and IFNL4-Î»G/TT. <i>Clinical Therapeutics</i> , 2019, 41, 2658-2659.	2.5	0